

March 23, 2016

# **MockV Solutions Awarded \$100,000 in Funding from TEDCO's Technology Commercialization Fund to Commercialize Lead Product**

**Rockville, MD – March 23, 2016** – MockV Solutions, Inc. (MockV or the Company), a biotechnology company developing non-infectious viral clearance prediction products that address the unmet needs of process development scientists as they establish biopharmaceutical manufacturing platforms, announced today that it has received approval for receipt of a \$100,000 convertible note from the Technology Commercialization Fund (TCF) of The Maryland Technology Development Corporation (TEDCO). As a result, the Company anticipates being able to commercialize its lead product, the MVM<sub>MVP</sub> Kit in 2017. For TEDCO's Press release on this award, visit <http://tedco.md/press/tedco-invests-1-7-million-in-17-maryland-startups/>

## **About TEDCO**

TEDCO is the go-to source for entrepreneurial support and guidance for start-ups and early-stage companies engaged in bringing innovative ideas to market. For over fifteen years, the organization has provided funding, mentoring and networking opportunities to support Maryland's innovation ecosystem. While founded by the Maryland General Assembly, TEDCO is an independent entity that makes seed/early-stage investments and manages private capital for angel and venture capital funds. It is frequently ranked as one of the most active seed/early-stage investors in the nation. The organization plays a key role in bringing research created in Maryland's educational institutions and federal laboratories into the commercial marketplace. For more information on TEDCO and its programs and resources, visit [www.TEDCO.md](http://www.TEDCO.md).

## **About MockV Solutions Inc.**

MockV Solutions, Inc. (MVS) is a biotechnology company commercializing non-infectious viral-surrogate tools to a variety of industries that currently rely on expensive and logistically challenging live virus analysis. MockV is developing a novel series of analytical assay kits which will enable biopharmaceutical process development scientists to study the efficacy of manufacturing techniques intended to remove or inactivate virus, a contaminant of great concern during the manufacturing of biopharmaceuticals. These products are only approved for clinical or commercial use after their manufacturing processes demonstrate sufficient viral clearance. Currently, this is accomplished through the use of live mammalian model viruses (ex. MVM and XMuLV) in expensive and logistically challenging "spiking studies". The lack of economical and accurate means of analyzing viral clearance during small scale process development increases the risk of failing viral clearance regulatory requirements - jeopardizing the timely approval of potentially life-altering therapies. MockV's lead product candidate, the MVM<sub>MVP</sub> Kit

contains a non-infectious “Mock Virus Particle” (MVP) that mimics the physicochemical characteristics of live infectious MVM, as well as reagents and components to quantify MVP in solution.

For further information regarding MockV Solutions, Inc., please visit the Company’s website at [www.mockvsolutions.com](http://www.mockvsolutions.com).